2seventy bio, Inc. (TSVT) entered a merger agreement on March 10, 2025, to be taken private by Bristol-Myers Squibb Company (BMY) in an all-cash deal valued at $286 million.
Under the terms of the agreement, Bristol Myers Squibb will commence a tender offer to acquire all outstanding shares of 2seventy bio for $5.00 per share in an all-cash transaction, representing a 78.57% premium from the stock’s last close.